Apollo Hospitals AILF

• A machine learning model developed using Indian data demonstrates higher accuracy compared to conventional risk scores.

• Feedback Loop from the prospective use in patients
• Comprehensive & Holistic Risk Assessment
• Validated at different National Institutions
• Integrated Clinical Decision Support Tool (What Next to Do)
• QMS: ISO 13485:2016 Certified, MDSAP Certification (In process)

Interpretation & Adoption Message

• AI Algorithm + Clinicians: This risk assessment tool has been built as an adjunct tool for physicians to identify global/holistic risk for Liver Fibrosis in NAFLD patients.
• Risk Identification and Prevention: This Risk Assessment Tool should not be used to diagnose Liver Fibrosis. Its limitations include already-diagnosed Liver fibrosis and currently under treatment.
• Where to use: This risk assessment tool has been prepared for use in Preventive Gastroenterology and Liver Disease Screening programs at Outpatient Clinics, Emergency Rooms, and Health Check Clinics, specifically those focusing on Non-Alcoholic Fatty Liver Disease.